NIH Grant
This article was originally published in The Tan Sheet
Executive Summary
InterHealth Nutraceuticals' Protykin, a trans-resveratrol ingredient that acts as a "pharmacological preconditioning agent for use in the treatment and prevention of heart attacks," is subject of a $100,000 grant from NIH, the firm announces Dec. 23. Protykin is plant extract that "has been shown to possess antimutagenic, antibacterial, gastroprotectant, cardioprotectant and phytoestrogen properties," according to Benicia, Calif.-based firm. Principal Investigator and InterHealth VP-R&D Debasis Bagchi, PhD, will partner with Dipak Das, PhD, of the University of Connecticut School of Medicine. Researchers expect to complete the study by the end of 2004, publish or present results in 2005...